Board of Directors
Kathy Rowlen, Ph.D. Chief Executive Officer and Co-founder at InDevR
Dr. Kathy Rowlen’s career has spanned both academia and business over the past three decades. Dr. Rowlen was an award-winning Professor of Chemistry at the University of Colorado in Boulder from 1991 to 2008; recognition included National Science Foundation Career Award, Beckman Foundation Young Investigator, Research and Creative Work Faculty Fellowship, and Inventor of the Year in 2006. Dr. Rowlen is inventor/co-inventor on numerous patents, has published over 100 scientific papers, and has given hundreds of scientific talks. After co-founding InDevR in 2003, Dr. Rowlen transitioned to a full-time position as its Chief Executive Officer in 2008. Under her leadership the company has experienced balanced growth and has successfully translated fundamental research into high-impact commercial products. InDevR has received a number of awards including Colorado Companies to Watch (2010), Innovative Company of the Year (BizWest IQ Awards, 2015), and Innovative Product of the Year (BizWest IQ Awards, 2015). Dr. Rowlen received her B.S. in Chemistry at Grand Valley State University and her Ph.D. in Chemistry at the University of Colorado, Boulder.
Shannon Rodriguez, Chief Operations Officer at InDevR
Shannon has led InDevR’s Finance and Operations departments since the company was founded, overseeing the design and implementation of policies to promote company culture and vision while maintaining and driving operational results. During her tenure, she has successfully managed more than $40 M in non-dilutive funding and contributed to the successful closing of venture capital financing. In her operational capacity, she has responsibility over a diverse variety of departments including Accounting, Quality, Manufacturing, Contract Services, Facilities, and Human Resources. Shannon oversees all financial aspects of cost control systems as well as compliance with public laws and regulations. Under her leadership, the company has consistently achieved the highest quality international standards and has diligently complied with all Federal Acquisition Regulations. In addition to providing leadership in the company’s strategic planning process and implementing new programmatic strategic initiatives as appropriate, she serves as liaison to corporate partners and works with the CEO and the company’s Board of Directors to ensure transparency in company programmatic strategies and challenges.
Shannon received her B.S. in Business Administration, Operations Management from the Leeds School of Business at the University of Colorado, Boulder. She also proudly serves as a Board Member for the GO3 Foundation, a novel education program in science, technology and the environment.
Michaël Reynier, Senior Vice President of Pharma Quality Control at bioMérieux
Mr. Reynier joined InDevR’s board in November 2022 as part of the bioMérieux investment in InDevR. Michaël is Senior Vice President of the Pharma Quality Control Business within the Industrial Microbiology Unit of bioMérieux where he leads a Global team of experts dedicated to developing and providing best in class Quality Control solutions for the Pharma Industry. Michaël holds degrees in cellular and molecular biology from the Ecole Normale Supérieure de la Rue d’Ulm (Paris, France) as well as engineering degrees in life sciences from AgroParisTech (Paris, France). Prior to joining bioMérieux, Michael held various responsibilities within the French public administration, in the field of economic development and competitiveness. He joined bioMérieux in 2011 as Special Adviser to the President and CEO and secretary of the Executive Committee. He then integrated the Industrial Microbiology Unit, where took over Strategy, Innovation and Portfolio Management responsibilities. Michaël was appointed as VP then SVP of the Pharma Quality Control Business in 2015.
Michael Chang, Principal at Adjuvant Capital
Mr. Chang is a Venture Partner at Adjuvant Capital, a life sciences investment firm focused on high-burden and neglected public health challenges, and is also founder and CEO of Tether Therapeutics, a biotechnology company developing next-gen inhalable mRNA therapeutics. Previously, Michael was at the Bill & Melinda Gates Foundation where he worked with the Global Health division to structure investments into biotech companies, leading academic centers, and other non-profit organizations to catalyze technological innovation in global health.
Before joining BMGF, Michael spent several years covering the specialty pharmaceuticals sector as an equity research analyst at Piper Jaffray in New York. Michael started his career in the investment banking practice at Stifel where he focused on mergers and acquisitions advising. He earned a BA in International Relations from Johns Hopkins University and is an MPH Candidate at the Johns Hopkins Bloomberg School of Public Health.
Nathalie Landry, Independent
Ms. Landry will be joining InDevR’s Board in January 2023 as an Independent Director. She is the former Executive Vice-President of Scientific and Medical Affairs at Medicago where she was responsible of R&D activities; analytical and process development; preclinical and clinical development and medical affairs. She is a C-suite executive with more than 25 years of experience at leading the development of new manufacturing technologies as well as innovative vaccines and pharmaceuticals from proof-of-concept to late-stage clinical trials and licensure. Under her leadership numerous vaccines were developed including norovirus, rotavirus and influenza vaccines, and most recently, she led the development of a Covid-19 vaccine that was approved by Health Canada. She also combines extensive management experience with companies supported by venture capital and institutional funds; a publicly-traded company resulting from an initial public offering; a company privatized through a merger and acquisition managed as a joint venture. Ms. Landry represented Medicago at numerous international conferences and is the co-author of several scientific publications and patents. Prior to joining Medicago she worked for a biotech company developing and producing anticancer compounds, where she held various positions. Nathalie earned a Master’s degree in microbiology-immunology in 1989 and an MBA in 1997, both from Laval University.